Status | Study |
Recruiting |
Study Name: Efficacy and Safety of KRN23 Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With X Linked Hypophosphatemia (XLH) Condition: X-Linked Hypophosphatemia Date: 2016-05-23 Interventions: Biological: KRN23 KRN23 is a r |
Completed |
Study Name: Growth Hormone Treatment in Children With Hypophosphatemic Rickets Condition: X Linked Hypophosphatemic Rickets Date: 2016-03-15 Interventions: Drug: norditropine simplex Other Name: growth hormone |
Active, not recruiting |
Study Name: Study of the Safety, Pharmacodynamics and Efficacy of KRN23 in Children From 1 to 4 Years Old With X-linked Hypophosphatemia (XLH) Condition: X-Linked Hypophosphatemia Date: 2015-12-06 Interventions: Drug: KRN23 |
Active, not recruiting |
Study Name: Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH) Condition: X-linked Hypophosphatemia Date: 2015-08-25 Interventions: Biological: KRN23 KRN23 is a recombinant human immunoglobulin G isotype 1 (IgG1) monoclonal antibody (mA |
Active, not recruiting |
Study Name: Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH) Condition: X-linked Hypophosphatemia Date: 2015-07-17 Interventions: Biological: KRN23 KRN23 is a r |
Enrolling by invitation |
Study Name: Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH) Condition: X-Linked Hypophosphatemia Date: 2014-12-03 Interventions: Drug: KRN23 KRN23 is a recombinant fully human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that b |
Recruiting |
Study Name: Iron Therapy for Autosomal Dominant Hypophosphatemic Rickets: A Pilot Project. Condition: Autosomal Dominant Hypophosphatemic Rickets Date: 2014-08-27 Interventions: Dietary Supplement: Iron All subjects will receive iron supplementation based on iron levels in the bloo |
Completed |
Study Name: A Study of KRN23 in Subjects With X-linked Hypophosphatemic Rickets/Osteomalacia Condition: X-linked Hypophosphatemic Rickets/Osteomalacia Date: 2014-07-02 Interventions: Drug: KRN23 Single SC administration on day 1: 0.3, 0.6 and 1.0 mg/kg |
Active, not recruiting |
Study Name: Study of KRN23, a Recombinant Fully Human Monoclonal Antibody Against FGF23, in Pediatric Subjects With X-linked Hypophosphatemia (XLH) Condition: X-linked Hypophosphatemia Date: 2014-06-09 Interventions: Drug: KRN23 |
Terminated |
Study Name: Cinacalcet for Fibroblast Growth Factor 23 (FGF23)-Mediated Hypophosphatemia (Hypophosphatemic Rickets) Condition: Osteomalacia Date: 2012-12-11 Interventions: Drug: Osteomalacia |